See Disclaimer

Research Commentary

This page is editorial commentary and informational synthesis of publicly available information for educational purposes and personal research only. It is observational of the emerging peptides research and broader functional wellness space in personalized precision medicine. Nothing here constitutes medical, legal, commercial, therapeutic, or analytical advice. See the full disclaimer at the bottom of this page for important details.

Peptides and Compounds

Evidence Tier	Compound	Type	Research Area	Mechanism & Studied Uses	Evidence Scoring	Adoption Scoring	Adverse Event Profile	Key Reasoning	Adverse Event Description
Elite	Tirzepatide ("GLP-2")	Peptide	Weight Loss / Metabolic	Dual GLP-1/GIP receptor agonist. Mechanism includes slowed gastric emptying, appetite suppression, and improved insulin sensitivity. Studied for chronic weight management, type 2 diabetes, and obstructive sleep apnea.	9.7	9.6	🟡	FDA-approved for chronic weight management and type 2 diabetes. Recently approved for obstructive sleep apnea. Human evidence: multiple Phase 3 RCTs including SURMOUNT-1, SURMOUNT-5 (head-to-head superiority over semaglutide), and SURMOUNT-OSA outcome anchor. Best-in-class evidence base with real-world discontinuation as the main caveat.	Severe GI side effects (nausea, vomiting, diarrhea) reported in ~50%+ of users — primary driver of real-world discontinuation. Gastroparesis cases documented. Rare pancreatitis signal. Thyroid C-cell tumor signal in rodents (boxed warning) has not materialized in human surveillance. Generally well-tolerated with proper dose titration.
Elite	Semaglutide ("GLP-1")	Peptide	Weight Loss / Metabolic	GLP-1 receptor agonist. Mechanism includes slowed gastric emptying, appetite suppression, and improved insulin sensitivity. Studied for chronic weight management, type 2 diabetes, and cardiovascular risk reduction.	9.5	9.5	🟡	FDA-approved for chronic weight management, type 2 diabetes, and cardiovascular risk reduction in patients with established CVD. Human evidence: gold-standard with STEP 1 (14.9% weight loss), SELECT (20% MACE reduction in 17,604 patients), and broad real-world surveillance. ~30% real-world 1-year discontinuation is the only material drag.	Same GI profile as tirzepatide. SELECT trial demonstrated cardiovascular protection — net safety positive at population scale. Gallbladder issues documented at higher doses. Same theoretical thyroid concern (boxed warning, unobserved in humans). Real-world adherence challenges reflect tolerability, not toxicity.
Elite	Retatrutide ("GLP-3")	Peptide	Weight Loss / Metabolic	Triple agonist (GLP-1, GIP, and glucagon receptors). Mechanism extends GLP-1 class by adding glucagon-mediated energy expenditure. Studied for weight management and metabolic disease.	9.3	9.1	🟡	Phase 3 trials completed; FDA approval pending. Human evidence: TRIUMPH-1 phase 3 showing 28.3% weight loss, 30.3% at two years — strongest weight loss outcomes ever documented in trials. Community use has accumulated ahead of approval through gray-market vendors.	Strongest weight loss in class corresponds to strongest GI side effects. Heart rate elevation modest but present. Phase 3 safety data still accumulating. Triple-agonist mechanism is novel — long-term safety profile is the unknown that keeps from green-zone profile.
Elite	HCG	Peptide Hormone	Sexual / Hormonal	Pregnancy hormone with LH-mimetic activity. Mechanism includes stimulation of Leydig cell testosterone production and testicular function preservation during exogenous testosterone use.	8.8	9.0	🟢	FDA-approved (legacy, pre-1962 NDA) for fertility indications. Off-label use as TRT-adjunct for testicular function preservation is widespread and decades-established. Human evidence: extensive across fertility and endocrinology literature. Universal TRT-clinic adoption.	Decades of safety data through fertility and TRT-adjunct use. Mild effects (acne, mood changes, water retention) at supraphysiologic doses. Rare ovarian hyperstimulation in fertility context. Generally excellent profile when dosed appropriately.
Elite	Tesamorelin	Peptide	Visceral Fat / GH-Axis	GHRH analog stimulating physiologic GH release. Mechanism includes pituitary-mediated GH pulse and downstream lipolysis specifically in visceral adipocytes.	8.5	7.4	🟡	FDA-approved for HIV-associated lipodystrophy; broader off-label use is mechanism-extrapolated. Human evidence: Phase 3 RCTs in HIV lipodystrophy showing 15-18% visceral adipose tissue reduction. Community adoption lower than evidence due to cost and injection-site reactions.	Injection-site reactions common (10%+ in trials) — major real-world tolerability issue. Joint pain, peripheral edema documented. IGF-1 elevation modest — theoretical cancer concern from sustained IGF-1 has not materialized in HIV-lipodystrophy patients tracked for years.
Elite	SS-31 (Elamipretide)	Peptide	Mitochondrial / Healing	Mitochondria-targeted peptide binding cardiolipin in the inner mitochondrial membrane. Mechanism includes stabilization of electron transport chain and restoration of energy production capacity. Studied for Barth syndrome and broader mitochondrial dysfunction.	8.4	6.8	🟢	FDA-approved September 2025 for Barth syndrome — first mitochondria-targeted peptide drug approved. Human evidence: Phase 3 trials in Barth syndrome plus earlier work in primary mitochondrial myopathy. Off-label adoption for broader mitochondrial support is recent and accelerating.	Recently FDA approved — passed rigorous safety review. Injection-site reactions are the main reported issue. Mitochondria-targeted mechanism is novel but clean. Limited long-term real-world surveillance data given recent approval.
Elite	HGH	Peptide Hormone	GH / Growth	Recombinant human growth hormone. Mechanism includes direct GH receptor activation and downstream IGF-1 production. Studied for growth hormone deficiency and AIDS wasting; off-label use for body composition and longevity.	8.2	8.6	🟠	FDA-approved for adult and pediatric GH deficiency, AIDS wasting, and several genetic syndromes. Off-label longevity/body composition use is widespread but not trial-supported. Human evidence: extensive across approved indications.	Real concerns: insulin resistance, carpal tunnel, edema, joint pain at supraphysiologic doses. Cancer-signaling concern (IGF-1 mediated) is theoretically real but observational data in adult GHD treatment is reassuring. Cardiac hypertrophy in long-term high-dose users. Safe at physiologic replacement doses; risk scales with dose and duration.
Strong	Tadalafil	Small Molecule	Sexual / Cardiovascular	PDE5 inhibitor. Mechanism includes increased nitric oxide signaling and vasodilation. Studied for erectile dysfunction, benign prostatic hyperplasia, and pulmonary arterial hypertension.	8.0	8.8	🟢	FDA-approved for ED, BPH, and pulmonary arterial hypertension. Decades of safety data and broad off-label adoption for vascular health and longevity protocols. Human evidence: extensive across all approved indications plus emerging research on cardiovascular and athletic applications.	Excellent safety profile across decades of broad use. Headache, flushing, mild GI most common. Hypotension with nitrates is the key contraindication. Rare priapism. Vision changes (NAION) very rare. Daily low-dose use exceptionally well-tolerated.
Strong	Liraglutide	Peptide	Weight Loss / Metabolic	First-generation GLP-1 receptor agonist. Same mechanism class as semaglutide but shorter half-life requiring daily dosing. Studied for weight management and type 2 diabetes.	7.8	6.5	🟡	FDA-approved 2010 for type 2 diabetes, 2014 for chronic weight management. Human evidence: extensive Phase 3 data. Now outclassed by semaglutide and tirzepatide in head-to-head comparisons; community has largely transitioned away.	Same GLP-1 class profile (GI side effects, theoretical thyroid signal). Slightly higher injection-site reaction rate than semaglutide due to daily dosing. Otherwise comparable safety.
Strong	PT-141 (Bremelanotide)	Peptide	Sexual / Hormonal	Melanocortin receptor agonist. Mechanism includes central nervous system activation of sexual arousal pathways. Studied for hypoactive sexual desire disorder.	7.8	7.4	🟡	FDA-approved 2019 for acquired generalized HSDD in premenopausal women. Off-label male use is mechanism-extrapolated. Human evidence: Phase 3 trials in HSDD; smaller studies in male sexual dysfunction.	Nausea is the dominant real-world issue — affects ~40% of users and drives discontinuation. Transient blood pressure elevation documented (contraindication in uncontrolled hypertension). Hyperpigmentation (focal melanocyte activation) reported with frequent use. Generally manageable with awareness.
Strong	Armodafinil	Small Molecule	Nootropic / Cognitive	R-enantiomer of modafinil with longer half-life. Mechanism involves dopamine reuptake inhibition and orexin system modulation. Studied for narcolepsy, sleep apnea, and shift-work sleep disorder.	7.6	7.8	🟡	FDA-approved 2007 for narcolepsy, OSA, and shift-work sleep disorder. Considered functionally similar to modafinil with longer-lasting effect. Human evidence: Phase 3 trials across approved indications plus off-label cognitive use in similar pattern to modafinil.	Similar profile to modafinil: SJS/TEN risk (very rare but serious). Headache, anxiety, insomnia common at higher doses. Cardiovascular effects modest. CYP3A4 induction affects oral contraceptives and other medications. Longer half-life can amplify side effects relative to modafinil if dosed without care.
Strong	Sermorelin	Peptide	GH / Growth	GHRH analog (29-amino-acid fragment). Mechanism includes physiologic GH pulse stimulation via pituitary. Studied for growth hormone deficiency and broader GH-axis support.	7.6	8.0	🟢	FDA-approved 1997 for pediatric GHD; withdrawn 2008 for commercial reasons (not safety). On the expected February 2026 HHS/FDA reclassification list moving from Category 2 back to Category 1, restoring legal compounding pharmacy access. Human evidence: pediatric GHD trials plus 25+ years of adult anti-aging clinic use.	Excellent safety profile across 25+ years of clinical use. Injection-site reactions mild. GH pulse is physiologic rather than supraphysiologic — avoids most HGH-related concerns. Headache occasionally reported. One of the cleaner profiles in the GH-axis category.
Strong	GHK-Cu	Peptide	Skin / Cosmetic / Healing	Copper-binding tripeptide endogenously present in human plasma. Mechanism modulates ~4,000 genes related to tissue remodeling, anti-inflammation, and skin regeneration. Studied for topical anti-aging, wound healing, and tissue repair.	7.6	8.4	🟢	Not FDA-approved as a drug; used as cosmetic ingredient and research peptide. On the expected February 2026 HHS/FDA reclassification list. Human evidence: strong for topical cosmetic use; injectable evidence thinner. The 4,000-gene mechanism is in vitro.	Topical use exceptionally well-tolerated across decades. Injectable use: mild injection-site reactions occasionally. Copper accumulation theoretical at very high sustained doses but unobserved at typical use. Minimal downside profile.
Strong	Modafinil	Small Molecule	Nootropic / Cognitive	Wakefulness-promoting agent. Mechanism involves dopamine reuptake inhibition and orexin system modulation. Studied for narcolepsy, sleep apnea, and shift-work sleep disorder.	7.5	8.4	🟡	FDA-approved for narcolepsy, OSA, and shift-work sleep disorder. Decades of human data including extensive military and medical use. Off-label cognitive enhancement use accumulated through millions of user-years.	Real concerns: SJS/TEN risk (very rare but serious — discontinue at any rash). Headache, anxiety, insomnia common at higher doses. Cardiovascular effects (BP, HR elevation) modest. CYP3A4 induction affects oral contraceptives and other medications. Decades of military/medical use establish broad safety; specific contraindications matter.
Strong	CJC-1295	Peptide	GH / Growth	GHRH analog with structural modifications for extended half-life. Mechanism stimulates pituitary GH release. Studied for GH-axis support, body composition, and recovery.	7.4	8.0	🟢	Not FDA-approved. On the expected February 2026 HHS/FDA reclassification list (without DAC; with DAC expected to remain restricted). Human evidence: clinical compounding use over a decade plus mechanism studies; thin RCT data. Decade-plus of TRT/longevity clinic adoption.	Without DAC: short-acting, physiologic GH pulse, excellent profile. Injection-site reactions mild. Sustained IGF-1 elevation minimal compared to HGH. CJC-1295 with DAC (different formulation, expected to remain on Cat 2) has more cumulative IGF-1 concerns.
Strong	Ipamorelin	Peptide	GH / Growth	Selective ghrelin receptor (GHS-R1a) agonist. Mechanism triggers GH pulse without raising cortisol or prolactin. Studied for GH-axis support and recovery.	7.4	8.2	🟢	Not FDA-approved. On the expected February 2026 HHS/FDA reclassification list. Human evidence: clinical compounding use over a decade plus selectivity studies; thin RCT data. The cleanest GHRP profile in the class.	The cleanest GH-axis peptide profile. No cortisol or prolactin spike (vs. older GHRPs). Injection-site reactions mild and rare. Selective GHS-R agonism without appetite stimulation. Decade-plus of clinical use without major safety signals.
Strong	BPC-157	Peptide	Injury Recovery / Gut Health	Synthetic peptide derived from a protein found in human gastric juice. Mechanism involves modulation of angiogenesis, growth factor expression, and inflammatory response. Studied for soft-tissue healing, gut barrier function, and inflammation.	7.0	9.0	🟢	Not FDA-approved. On the expected February 2026 HHS/FDA reclassification list — major regulatory signal reflecting HHS reconsideration of the 2023 safety basis. Human evidence: extensive preclinical (200+ animal studies, primarily from Sikiric lab in Zagreb) with limited human trials; widespread clinic and community use for 15+ years.	The VEGF/angiogenesis cancer-promotion theoretical concern has not materialized in 15+ years of widespread community and clinical use. The same VEGF mechanism that drives healing creates the theoretical concern — yet observational evidence across thousands of users hasn't shown elevated cancer incidence. Healthy lifestyle factors (anti-inflammatory diet, antioxidants like resveratrol/curcumin/EGCG, exercise) further mitigate any theoretical risk. Real safety profile is excellent.
Strong	CJC+Ipa Blend	Peptide Blend	GH / Growth	Combination of CJC-1295 (GHRH analog) and Ipamorelin (ghrelin receptor agonist). Mechanism combines synergistic pathways for GH pulse amplification. The clinic-standard GH-axis pairing.	7.0	8.4	🟢	Not FDA-approved. Both components on the expected February 2026 HHS/FDA reclassification list. Human evidence: component-level studies plus decade of clinical compounding use as standard GH-axis pairing.	Inherits clean profiles of both components. Decade-plus of clinical use as standard GH-axis pairing. Mild injection-site reactions occasionally. Synergistic GH pulse without supraphysiologic IGF-1 elevation. One of the safest stacks in the space.
Solid	MK-677 (Ibutamoren)	Small Molecule	GH / Growth	Oral ghrelin receptor agonist. Mechanism stimulates GH and IGF-1 release without injection. Studied for GH deficiency, sarcopenia, and recovery.	6.7	7.8	🟡	Not FDA-approved; in clinical trials for various indications. Human evidence: Phase 2 studies in elderly subjects showing GH/IGF-1 elevation and lean mass effects; longer studies in osteoporosis and GH deficiency. Strong bodybuilding and longevity community adoption.	Real concerns: appetite stimulation can drive significant weight gain, water retention, mild insulin resistance, transient lethargy. Long-term IGF-1 elevation concern. CHF signal in elderly trial population. Oral route increases convenience but doesn't reduce systemic risk profile.
Solid	Mazdutide	Peptide	Weight Loss / Metabolic	Dual GLP-1/glucagon receptor agonist. Mechanism extends GLP-1 with glucagon-mediated metabolic effects. Studied for obesity and type 2 diabetes primarily in Chinese trials.	6.5	5.0	🟡	Not FDA-approved; approved in China 2025 for chronic weight management. Human evidence: Phase 3 trials primarily in Chinese populations showing meaningful weight loss; Western trial data accumulating. Limited current Western community adoption.	Inherits GLP-1 class GI profile plus glucagon-related effects (HR elevation, mild glucose dysregulation in some patients). Phase 3 safety data still being characterized in Western populations.
Solid	CagriSema	Peptide Blend	Weight Loss / Metabolic	Fixed-dose combination of semaglutide and cagrilintide (amylin analog). Mechanism combines GLP-1 with amylin-mediated satiety. Studied for obesity and metabolic disease.	6.5	5.5	🟡	Not FDA-approved; under FDA review 2026. Human evidence: REDEFINE-1 phase 3 showing 23% weight loss but REDEFINE-4 missed head-to-head endpoint vs. semaglutide monotherapy. Community adoption limited pending approval.	GLP-1 class GI profile plus amylin-related effects (additional satiety, slight HR elevation). Phase 3 safety data still being characterized. REDEFINE-4 miss complicates risk-benefit picture if efficacy is not superior to semaglutide monotherapy.
Solid	Cagrilintide	Peptide	Weight Loss / Metabolic	Long-acting amylin analog. Mechanism includes amylin-mediated satiety, gastric emptying delay, and glucagon suppression. Studied as monotherapy and in CagriSema combination.	6.3	4.8	🟡	Not FDA-approved as monotherapy. Human evidence: Phase 2 monotherapy trials showing modest weight loss; primarily developed as combination component. Community use as standalone is limited.	Generally well-tolerated as monotherapy. GI effects (nausea, decreased appetite) similar to but milder than GLP-1 class. Heart rate effects modest. Limited long-term standalone data.
Solid	TB-500	Peptide	Injury Recovery	Short thymosin beta-4 related peptide. Mechanism involves cell migration, angiogenesis, and tissue repair signaling. Studied for soft tissue, tendon, and muscle recovery.	6.4	8.0	🟡	Not FDA-approved for human use; banned in equestrian sport (USEF 2014). On the expected February 2026 HHS/FDA reclassification list. Human evidence: thin RCT data; extensive community use over 15+ years for soft-tissue recovery.	Theoretical tumor-promotion concern from animal studies has more preclinical support than the BPC-157 equivalent concern. Real-world community use over 15+ years hasn't shown obvious cancer signal. Caution warranted in active malignancy contexts. Injection-site reactions mild.
Solid	LDN (Low-Dose Naltrexone)	Small Molecule	Anti-inflammatory / Autoimmune	Low-dose opioid antagonist. Mechanism includes transient mu-opioid antagonism leading to endorphin upregulation and microglial modulation. Studied for autoimmune conditions, chronic pain, and fibromyalgia.	6.3	7.8	🟢	Naltrexone FDA-approved at higher doses for opioid and alcohol dependence; low-dose off-label use is widespread in functional medicine. Human evidence: multiple small RCTs in fibromyalgia, Crohn's disease, MS, and chronic pain plus growing observational cohorts. Likely moves toward stronger evidence tier as more trials publish.	Exceptional safety profile at low doses. Vivid dreams and sleep disturbance most common early side effects, usually resolving in 1-2 weeks. Contraindicated in active opioid use (will precipitate withdrawal). One of the safest off-label compounds in this space.
Solid	Cerebrolysin	Peptide Blend	Nootropic / Neuroprotective	Porcine-derived neuropeptide complex containing low-molecular-weight peptides and amino acids. Mechanism includes neurotrophic factor mimicry and neuroprotection. Studied for stroke, traumatic brain injury, and dementia.	6.3	6.8	🟢	Approved in many countries (Russia, China, Korea, Germany, Mexico, others) for ischemic stroke, dementia, and TBI; not FDA-approved. Human evidence: numerous RCTs including Cochrane reviews showing mixed but generally favorable outcomes in stroke recovery and TBI. Decades of clinical use globally.	Decades of international clinical use with favorable safety profile. Injection-site reactions and mild flu-like symptoms most common. Rare allergic reactions due to porcine origin. Contraindicated in epilepsy without careful titration.
Solid	Humanin	Peptide	Mitochondrial / Longevity	Mitochondrial-derived peptide encoded within mitochondrial DNA. Mechanism includes cytoprotection, IGF-binding modulation, and mitochondrial signaling. Studied for neuroprotection, metabolic disease, and longevity biomarker research.	6.2	5.5	🟢	Not FDA-approved. Human evidence: emerging research showing inverse association between Humanin levels and age-related disease; analog studies in metabolic and neurodegenerative contexts. Newer to community use than MOTS-c but conceptually related.	Endogenous mitochondrial-derived peptide. Limited human safety data but available trial data clean. No significant adverse event patterns from early human studies or community use.
Solid	KLOW Blend	Peptide Blend	Skin / Healing	Four-peptide stack: KPV + GHK-Cu + BPC-157 + TB-500. Component logic combines skin/collagen support, anti-inflammation, gut/tissue healing, and tissue repair. Popular functional medicine formulation.	6.2	7.6	🟢	Not FDA-approved. Components on expected reclassification list. Human evidence: component-level studies; no blend-specific trials. Strong functional medicine clinic adoption as comprehensive recovery/skin protocol.	Inherits component profiles. KPV is anti-inflammatory and well-tolerated. Component-level safety established; blend-specific issues haven't emerged.
Solid	BPC+TB Blend (Wolverine Stack)	Peptide Blend	Injury Recovery	Combination of BPC-157 and TB-500. Mechanism combines tissue repair pathways for synergistic recovery effects. Popularly named "Wolverine stack" in community use.	6.2	8.2	🟡	Not FDA-approved. Both components on expected reclassification list. Human evidence: component-level only; no blend-specific trials. Massive community adoption in injury recovery contexts.	Inherits TB-500's theoretical tumor concern (dominant safety consideration). Otherwise excellent component profiles. Blend doesn't create new safety issues but TB-500 component drives the yellow classification. Caution warranted in active malignancy contexts.
Solid	Thymosin Alpha-1	Peptide	Immune / Anti-inflammatory	28-amino-acid thymic peptide. Mechanism modulates T-cell function and innate immune response. Studied for chronic viral infections, immune support, and adjuvant cancer therapy.	6.0	7.5	🟢	Approved in 35+ markets for chronic hepatitis B; not FDA-approved. On the expected February 2026 HHS/FDA reclassification list. Human evidence: Phase 3 trials for hepatitis B plus extensive use in cancer adjuvant and chronic infection contexts internationally.	Excellent safety profile across 35-market approval history and decades of clinical use. Mild injection-site reactions. Immune activation is the mechanism — relative contraindication in active autoimmune flares due to potential exacerbation. One of the cleanest profiles in immune-modulation space.
Solid	Hexarelin	Peptide	GH / Growth	Synthetic hexapeptide GHRP. Mechanism includes ghrelin receptor agonism for GH release, with cardioprotective effects in some studies. Older generation GHRP.	5.9	5.5	🟡	Not FDA-approved. Human evidence: clinical studies in GH deficiency and cardiac applications; mechanism studies. Now less popular than ipamorelin due to side effect profile but maintains niche use.	Causes meaningful cortisol and prolactin elevation similar to GHRP-2/6. Receptor desensitization with extended use is a real issue. Cardioprotective signals in some studies are interesting but outweighed by side effect profile for general use.
Solid	Hydroxychloroquine	Small Molecule	Autoimmune / Anti-inflammatory	Antimalarial with immune-modulating effects. Mechanism includes lysosomal pH modulation and reduced antigen presentation. Studied for malaria, lupus, rheumatoid arthritis, and other autoimmune conditions.	5.8	6.0	🟠	FDA-approved for malaria prophylaxis/treatment, lupus, and rheumatoid arthritis. COVID off-label use failed in major RCTs (RECOVERY, SOLIDARITY). Human evidence: extensive across approved indications; substantial negative evidence for COVID.	Real concerns: retinopathy with chronic use (requires annual eye exams), QT prolongation, hepatotoxicity at high doses. Cardiotoxicity contributed to COVID-trial negative results. Safe for label uses with monitoring; less safe for short-term high-dose off-label use.
Solid	Oxytocin	Peptide Hormone	Sexual / Hormonal / Bonding	Nonapeptide hormone produced by the hypothalamus. Mechanism includes social bonding, lactation, and labor effects. Studied for obstetric use and off-label social/anxiety applications.	5.8	6.4	🟢	FDA-approved 1962 for labor induction and postpartum hemorrhage. Off-label intranasal use for social bonding, anxiety, and sexual function has mixed evidence. Human evidence: extensive for obstetric uses; smaller trials for off-label applications.	Excellent profile in obstetric use at controlled doses. Off-label intranasal/injection use: occasional headache, transient BP changes, GI upset. Water retention/hyponatremia at high doses (rare). Generally well-tolerated for off-label applications.
Solid	KPV	Peptide	Anti-inflammatory / Gut Health	Tripeptide derived from alpha-MSH C-terminus. Mechanism includes picomolar NF-kB inhibition without melanocortin receptor activity. Studied for IBD, eczema, and other inflammatory conditions.	5.8	7.0	🟢	Not FDA-approved. On the expected February 2026 HHS/FDA reclassification list. Human evidence: preclinical mechanism strong; small clinical studies in IBD and inflammatory conditions. Functional medicine adoption growing for gut and inflammation indications.	Tripeptide derived from α-MSH without tanning or appetite effects. Anti-inflammatory mechanism is clean. Excellent tolerability profile in available clinical data. No significant adverse event patterns documented.
Solid	Kisspeptin-10	Peptide	Sexual / Hormonal	Decapeptide stimulating GnRH release. Mechanism includes hypothalamic kisspeptin receptor activation. Studied for fertility, libido, and reproductive hormone disorders.	5.8	5.0	🟢	Not FDA-approved. Human evidence: strongest trials used the longer KP-54 analog rather than KP-10 itself; KP-10 has smaller mechanism and dose-finding studies. Community adoption limited and often based on KP-54 evidence misattributed.	Limited but clean safety data in available trials. Endogenous peptide pathway with physiologic mechanism. No significant adverse event patterns. Smaller community use means less real-world surveillance data.
Solid	Semax	Peptide	Nootropic / Neuroprotective	Synthetic heptapeptide derived from ACTH (4-10) fragment. Mechanism modulates BDNF, NGF, dopamine, and serotonin pathways. Intranasal administration. Studied for cognitive enhancement, stroke recovery, and mood support.	5.8	7.4	🟢	Approved in Russia since 1982 for ischemic stroke, cognitive disorders, and other neurologic indications. On the expected February 2026 HHS/FDA reclassification list. Human evidence: Russian RCTs and registry data over four decades; thin Western trial data.	40+ years of Russian clinical use without major safety signals is meaningful real-world data. Mild side effects (occasional headache, irritability) at higher doses. Intranasal route generally well-tolerated. Multi-decade foreign use history is the strongest safety signal for this compound.
Solid	Selank	Peptide	Nootropic / Anxiolytic	Synthetic heptapeptide derived from tuftsin. Mechanism includes GABA-modulating and BDNF-related effects. Intranasal administration. Studied for generalized anxiety disorder and mild depression.	5.8	7.2	🟢	Approved in Russia since 2004 for anxiety disorders. On the expected February 2026 HHS/FDA reclassification list. Human evidence: Russian head-to-head trials versus benzodiazepines showing comparable anxiolysis without sedation/dependence; thin Western trial data.	Two decades of Russian clinical use for anxiety without major safety signals. No sedation, no dependence, no withdrawal — significantly cleaner profile than benzodiazepines for the same indication. Mild headache occasionally reported.
Solid	Larazotide	Peptide	Gut Health	Octapeptide zonulin antagonist. Mechanism includes tight junction modulation and reduced intestinal permeability. Studied for celiac disease and leaky gut conditions.	5.7	5.5	🟢	Not FDA-approved; Phase 3 trial in celiac disease did not meet primary endpoint. Human evidence: Phase 3 in celiac plus mechanism studies. Continues development for other indications.	Generally well-tolerated in trials. Mild GI effects most commonly reported. No significant safety signals across multiple Phase 2/3 studies.
Solid	Bromantane	Small Molecule	Nootropic / Adaptogen	Adamantane derivative with dopamine and serotonin modulation. Mechanism includes tyrosine hydroxylase activation and adaptogenic effects. Studied for asthenia, anxiety, and fatigue.	5.5	6.2	🟡	Approved in Russia for asthenia. Not FDA-approved. Human evidence: Russian RCTs for asthenia and anxiety; thin Western data. Multi-decade foreign clinical use.	Dopamine/serotonin modulation creates theoretical concerns about long-term receptor dynamics with chronic use. Russian clinical data shows good short-to-medium term tolerability. Less safety data on multi-year use. Caution warranted combining with serotonergic medications.
Solid	Methylene Blue	Small Molecule	Mitochondrial / Nootropic	Phenothiazine dye with alternative electron carrier function. Mechanism at low doses includes mitochondrial electron transport support and MAO-A inhibition. Studied for methemoglobinemia and explored for cognition and neurodegenerative disease.	5.5	7.0	🟠	FDA-approved for methemoglobinemia and as a surgical dye. Off-label low-dose use for cognitive and mitochondrial support is community-driven. Human evidence: TauRx Alzheimer's trials missed primary endpoints with interesting secondary signals; smaller cognitive studies.	Serotonin syndrome risk with SSRIs/SNRIs is the major concern (contraindicated combination). G6PD deficiency contraindication. High doses cause hemolytic anemia, paradoxical methemoglobinemia at very high doses. Urine/sweat discoloration is cosmetic but disconcerting. Safe at low nootropic doses without serotonergic medications.
Solid	LL-37	Peptide	Anti-infection / Healing	Human cathelicidin antimicrobial peptide. Mechanism includes direct microbial killing, biofilm disruption, and wound healing modulation. Studied for chronic infection, wound healing, and biofilm-related conditions.	5.5	6.2	🟠	Not FDA-approved. Expected to REMAIN on FDA Category 2 (continued restriction from compounding). Human evidence: preclinical and limited clinical evidence for wound healing and chronic infection. Mixed cancer cell-line effects (pro-tumorigenic in some cancers, anti-tumorigenic in others) is the key concern driving continued restriction.	Mixed cancer cell-line effects across studies is the key concern driving continued Category 2 restriction. FDA's caution appears warranted given inconsistent in vitro signals. Long-term human safety data limited. Caution warranted with active cancer history.
Solid	Flmodafinil	Small Molecule	Nootropic / Cognitive	Bisfluoro analog of modafinil. Mechanism extrapolated from modafinil. Higher potency, faster onset, longer half-life reported in limited studies.	5.5	6.5	🟡	Not approved in any jurisdiction; sold as research chemical. Human evidence: limited pharmacokinetic studies; no controlled efficacy trials. Mechanism extrapolated from modafinil. Growing community use as research chemical.	Extrapolated safety from modafinil but without controlled trials. Higher potency means dose-response uncertainty. Same theoretical SJS concern as modafinil (very rare). Cardiovascular effects likely similar to parent compound. Less real-world surveillance than modafinil.
Solid	Ivermectin	Small Molecule	Anti-parasitic / Anti-inflammatory	Macrocyclic lactone antiparasitic. Mechanism includes glutamate-gated chloride channel activation in parasites; emerging research on mammalian anti-inflammatory and cancer-adjuvant pathways.	5.5	6.2	🟢	FDA-approved for various parasitic infections; decades of WHO mass-administration safety data. Off-label COVID use failed in major RCTs. Cancer-adjuvant preclinical signals emerging without controlled trials. Human evidence: extensive for parasitic indications; substantial negative evidence for COVID.	Exceptional safety profile at parasitic doses. Higher off-label doses for COVID/cancer use have caused liver enzyme elevation, GI distress, neurological effects (rare). Drug interactions through CYP3A4. Safe at label doses; off-label dosing increases risk.
Solid	LIPO-C	Compounded Blend	Weight Loss / Liver	Compounded injection typically containing methionine, inositol, choline, and B-vitamins. Mechanism includes lipotropic factor support for hepatic fat metabolism. Used in weight loss clinics.	5.5	6.5	🟢	Not FDA-approved as drug; available through compounding pharmacies. Human evidence: thin clinical trial data; mechanism-extrapolated from component lipotropic factor research. Wide weight-loss-clinic adoption as adjunct to caloric restriction.	Generally well-tolerated. Mild injection-site reactions most common. Methionine load can be inappropriate for certain genetic variants (MTHFR considerations). No significant systemic safety concerns at typical doses.
Solid	L-Carnitine	Amino Acid Derivative	Mitochondrial / Metabolic	Naturally occurring amino acid derivative essential for fatty acid transport into mitochondria. Mechanism includes carnitine palmitoyltransferase activation and fat oxidation support. Studied for cardiovascular disease, metabolic conditions, and athletic performance.	5.5	6.5	🟢	Available as supplement and prescription (levocarnitine, FDA-approved for primary carnitine deficiency). Human evidence: extensive across cardiovascular, metabolic, and supplement contexts. Acetyl-L-carnitine has separate evidence base for cognitive applications.	Excellent safety profile at typical supplement doses. TMAO production from gut bacteria has been raised as theoretical cardiovascular concern but evidence is mixed. GI upset at higher doses. Fish-like body odor at very high doses.
Solid	MOTS-c	Peptide	Mitochondrial / Metabolic	16-amino-acid mitochondrial-derived peptide. Mechanism includes AMPK activation, metabolic regulation, and exercise-mimetic signaling. Studied for metabolic disease, insulin sensitivity, and exercise physiology.	5.4	5.8	🟢	Not FDA-approved. On the expected February 2026 HHS/FDA reclassification list. Human evidence: mechanism studies and early human trials emerging; strong mouse data. Community adoption modest but building.	Endogenous mitochondrial peptide. Limited human safety data but available trial data clean. No significant adverse event patterns emerging from early human studies or community use.
Solid	Glow Blend	Peptide Blend	Skin / Cosmetic	Three-peptide skin/hair stack: GHK-Cu + KPV + glutathione. KLOW formulation without the tissue-healing peptides. Popular skin/aesthetic functional medicine formulation.	5.5	7.0	🟢	Not FDA-approved. Components on expected reclassification list. Human evidence: component-level only; no blend-specific trials. Skin/hair clinic use widespread.	Inherits component profiles. All components have excellent tolerability. No blend-specific issues identified.
Solid	NAD+	Coenzyme	Mitochondrial / Longevity	Nicotinamide adenine dinucleotide — essential cellular coenzyme for energy production, DNA repair, and sirtuin activation. IV infusion is the longevity-clinic standard delivery; oral NMN/NR are precursor alternatives.	5.0	6.8	🟡	Not a peptide; endogenous coenzyme. Available through compounding pharmacies and supplement channels; no FDA drug approval needed for cofactor use. Human evidence: small studies on IV bioavailability questions; broader oral precursor (NMN, NR) trials accumulating. Clinic-staple status outpaces controlled evidence.	IV infusion can cause uncomfortable side effects during administration (flushing, chest pressure, nausea — usually dose-rate dependent and resolves with slower infusion). No long-term safety concerns documented at typical clinic doses. Bioavailability questions affect efficacy more than safety.
Solid	VIP	Peptide	Anti-inflammatory / CIRS	28-amino-acid endogenous peptide with vasodilation and anti-inflammatory effects. Mechanism includes VPAC1/VPAC2 receptor activation. Studied for COVID ARDS (Aviptadil) and used off-label for CIRS protocols.	5.0	5.8	🟡	Not FDA-approved (Aviptadil failed Phase 3 for COVID-19 ARDS). Human evidence: Phase 3 trial in ARDS plus mechanism studies; CIRS use is community-driven through Shoemaker protocols.	Vasodilation effects can cause hypotension, especially intranasal at higher doses. Aviptadil trial data showed acceptable safety in ARDS context. Limited long-term data on chronic intranasal use.
Limited	Melanotan II	Peptide	Skin / Sexual	Synthetic melanocortin receptor agonist. Mechanism includes melanocyte stimulation (tanning) and central sexual arousal effects. Not approved in any jurisdiction.	4.8	6.0	🟠	Not approved in any jurisdiction; sold as research chemical. Expected to REMAIN on FDA Category 2. Human evidence: small studies on tanning and sexual function; significant gray-market use.	Real concerns: nausea (very common, ~70% of users), blood pressure elevation, melanocyte activation including new/changing moles requiring dermatologic monitoring. Theoretical melanoma risk remains unresolved given chronic melanocyte stimulation. Priapism documented. Rhabdomyolysis case reports.
Limited	P21	Peptide	Nootropic / Neuroprotective	Synthetic peptide derived from a neurotrophic factor analog found in Cerebrolysin. Mechanism includes neurogenesis support similar to Cerebrolysin but in shorter peptide form. Studied for cognitive support.	4.7	5.0	🟢	Not FDA-approved. Human evidence: preclinical mechanism studies; Cerebrolysin parent compound has stronger evidence. Limited community use as research peptide.	Limited safety data as standalone compound. Inherits some Cerebrolysin tolerability characteristics. No significant adverse event patterns documented in available reports.
Limited	PE-22-28	Peptide	Mood / Depression	Spadin-related peptide. Mechanism includes TREK-1 channel inhibition for antidepressant effects without delayed onset of conventional SSRIs. Studied for major depression in preclinical models.	4.5	4.8	🟡	Not FDA-approved; preclinical compound entering human research. Human evidence: emerging; primarily preclinical to date. Limited community use, emerging interest as rapid-onset antidepressant research compound.	Limited human safety data. Preclinical work shows clean profile relative to SSRIs. Long-term effects not characterized in humans.
Limited	AOD9604	Peptide Fragment	Weight Loss	HGH fragment 176-191 (C-terminal fragment of growth hormone). Mechanism proposed as lipolytic without anabolic effects. Phase 2b trial for obesity failed primary endpoint.	4.5	5.0	🟢	On the expected February 2026 HHS/FDA reclassification list — notable because the strongest trial of this compound did not support efficacy claims. Human evidence: Phase 2b failed to demonstrate weight loss benefit. Reclassification reflects access policy, not new efficacy evidence.	Excellent safety profile from Phase 2b trial — the issue was lack of efficacy, not safety. Mild side effects only. The compound is safe; it simply did not demonstrate the claimed fat-loss effects in the controlled trial.
Limited	ARA-290	Peptide	Anti-inflammatory / Neuropathy	11-amino-acid erythropoietin-derived peptide. Mechanism includes innate repair receptor agonism without erythropoietin receptor activation. Studied for diabetic neuropathy, chronic inflammation, and tissue repair.	4.5	5.8	🟢	Not FDA-approved; sponsor dissolved before Phase 3. Human evidence: Phase 2 trials for diabetic neuropathy showing favorable signals; multiple smaller studies. Growing community use for neuropathy and chronic inflammation.	Clean safety profile from Phase 2 trials. No significant adverse event patterns. Innate repair receptor mechanism is selective (avoiding erythropoietin-receptor safety issues). Handling complexity (buffering issues) is a quality-of-product concern, not a fundamental safety concern.
Limited	Mebendazole	Small Molecule	Anti-parasitic / Cancer-adjuvant	Benzimidazole antiparasitic. Mechanism includes tubulin binding and microtubule disruption — same mechanism that has driven cancer-adjuvant research interest. Studied for various parasitic infections and explored for oncology applications.	4.5	5.5	🟡	FDA-approved for various parasitic infections. Off-label cancer-adjuvant use is mechanism-extrapolated. Human evidence: extensive for parasitic indications; preclinical evidence and small case reports for oncology applications; no controlled cancer trials.	Excellent safety at antiparasitic doses (label use). Off-label cancer-adjuvant doses (higher and longer-term) have caused hepatotoxicity in some cases. Liver function monitoring recommended for off-label use.
Limited	Triptorelin	Peptide	Sexual / Hormonal	GnRH agonist. Mechanism includes sustained GnRH receptor activation leading to gonadotropin suppression after initial flare. Studied for prostate cancer, central precocious puberty, and endometriosis.	4.2	4.5	🟡	FDA-approved for advanced prostate cancer; broader off-label use is mechanism-extrapolated. Off-label PCT-restart use is narrow. Human evidence: extensive for approved indications.	Hot flashes, decreased libido, and mood changes from gonadal suppression are expected pharmacologic effects. Bone density loss with chronic use. Cardiovascular concerns at long-term suppression. PCT-restart use is short-duration so most chronic concerns don't apply.
Limited	Epithalon	Bioregulator	Longevity / Sleep	Khavinson tetrapeptide bioregulator (Ala-Glu-Asp-Gly). Mechanism includes telomerase activation, pineal modulation, and melatonin regulation. Studied for longevity, sleep, and age-related decline.	4.2	7.2	🟢	Not approved as drug; available through compounding pharmacies and research channels. Human evidence: Russian clinical research from Khavinson lab over 30+ years; lifespan claims from one cohort never replicated outside the originating lab. Wide longevity-community adoption.	30+ years of Russian clinical use without major safety signals. No significant adverse events documented. Endogenous bioregulator mechanism unlikely to drive acute toxicity. Long-term safety data limited to Russian sources, but multi-decade use pattern is reassuring.
Limited	HMG	Peptide Hormone	Sexual / Hormonal / Fertility	Combination of FSH and LH purified from postmenopausal urine. Mechanism includes direct gonadotropin stimulation. Studied for fertility induction in both sexes.	4.0	5.0	🟡	FDA-approved for ovulation induction and fertility support. Off-label use in TRT-adjunct and PCT contexts is mechanism-extrapolated. Human evidence: extensive for fertility indications.	Standard fertility-medication side effect profile (mood changes, OHSS in females, occasional injection-site reactions). Generally well-tolerated. Concerns mostly relate to off-label hormonal manipulation contexts rather than the compound itself.
Limited	Gonadorelin	Peptide	Sexual / Hormonal	Synthetic gonadotropin-releasing hormone. Mechanism includes pulsatile GnRH receptor activation. US labels now restricted to veterinary use; off-label TRT-adjunct use is community-driven.	4.0	5.5	🟢	FDA-approved 1982 for diagnostic use, later withdrawn from human market. Current US labels are animal-drug products. Off-label human use as HCG alternative in TRT contexts is widespread. Human evidence: physiologic mechanism well-characterized.	Endogenous GnRH analog. Excellent safety profile in clinical use. Mild injection-site reactions, occasional headache. Pulsatile dosing pattern is well-tolerated.
Limited	Melanotan I (Afamelanotide)	Peptide	Skin / Cosmetic	First-generation melanocortin agonist. Mechanism includes melanocyte stimulation for protective pigmentation. Studied for erythropoietic protoporphyria.	4.0	5.5	🟡	FDA-approved for erythropoietic protoporphyria — ultra-narrow rare disease indication. Off-label tanning use is mechanism-extrapolated. Human evidence: Phase 3 trials in EPP plus mechanism studies; thin off-label data.	Better safety profile than Melanotan II (less BP and GI effects). Melanocyte stimulation creates same theoretical melanoma concern. Mole monitoring recommended with chronic use. Approved for EPP without major safety issues at therapeutic doses.
Limited	AHK-Cu	Peptide	Skin / Hair	Copper tripeptide marketed for hair growth. Mechanism extrapolated from GHK-Cu pathway. Less studied than parent GHK-Cu compound.	4.0	5.8	🟢	Not FDA-approved. Human evidence: thinner than GHK-Cu; topical hair-regrowth signal exists in small studies. Community use in hair-loss protocols common.	Topical use very well-tolerated. Mild skin irritation occasionally. Copper accumulation theoretical at very high sustained doses. Similar clean profile to GHK-Cu.
Limited	Thymulin	Peptide	Immune / Anti-inflammatory	Zinc-bound thymic peptide. Mechanism includes T-cell maturation and immune regulation. Studied in older immunology literature; thin contemporary data.	4.0	5.0	🟢	Not FDA-approved. Human evidence: older European clinical use; thin contemporary research. Limited current community presence relative to Thymosin Alpha-1.	Endogenous thymic peptide. Limited contemporary safety data but historical clinical use clean. No significant adverse event patterns.
Limited	Nortadalafil	Small Molecule	Sexual	Demethylated designer analog of tadalafil. Same PDE5 inhibition mechanism extrapolated. Often appears as adulterant in supplements rather than as standalone product.	4.0	4.5	🟠	Not approved in any jurisdiction; sold as research chemical or appears as adulterant. Human evidence: no controlled studies; mechanism extrapolated from tadalafil. FDA enforcement actions for adulterated supplements.	Quality-control issues are the dominant safety concern — adulterated supplements have caused unexpected cardiovascular events when actual content didn't match labeling. PDE5 mechanism itself is well-tolerated; supply-chain integrity is the real risk.
Limited	Cartalax	Bioregulator	Joint / Cartilage	Khavinson tetrapeptide cartilage bioregulator. Mechanism includes peptide-bioregulator modulation of cartilage tissue. Studied for joint and cartilage repair.	3.9	5.5	🟢	Not approved as drug in US. Human evidence: Russian research from Khavinson lab; no Western replication; no controlled human trials. Community use in joint/cartilage protocols growing.	No significant adverse event patterns documented. Endogenous peptide bioregulator mechanism unlikely to drive acute toxicity. Long-term safety data limited to Russian sources.
Limited	Pinealon	Bioregulator	Longevity / Neuroprotection	Khavinson tripeptide bioregulator. Mechanism includes pineal-derived neuroprotection signaling. Studied for cognitive aging and neurodegeneration.	3.9	5.8	🟢	Not approved as drug in US. Human evidence: Russian research from Khavinson lab; even thinner data than Epithalon. Same single-lab pattern. Community use in neuroprotection contexts modest.	Same Khavinson safety pattern as Epithalon. No significant adverse events documented. Multi-decade Russian use without major signals.
Limited	Cortagen	Bioregulator	Nootropic / Neuroprotective	Khavinson tetrapeptide bioregulator (Ala-Glu-Asp-Pro). Mechanism includes peptide-bioregulator modulation of brain tissue. Studied for cognitive function and neurological recovery.	3.8	5.5	🟢	Not approved as drug in US. Human evidence: Russian Khavinson lab research; standard single-lab dominance pattern. Modest community use in nootropic contexts.	Standard Khavinson bioregulator safety pattern. No significant adverse events documented. Long-term safety data limited to Russian sources.
Limited	Thymagen	Bioregulator	Immune	Khavinson tetrapeptide bioregulator targeting thymus tissue. Mechanism includes thymus-related immune signaling. Studied for immune support and senescence.	3.8	5.0	🟢	Not approved as drug in US. Human evidence: Russian Khavinson lab research only. Community use modest, primarily in immune-aging contexts.	Standard Khavinson bioregulator safety pattern. No significant adverse event patterns documented.
Limited	Livagen	Bioregulator	Immune / Liver	Khavinson tetrapeptide bioregulator targeting liver and immune tissues. Mechanism includes peptide-bioregulator modulation of hepatic and immune function.	3.8	5.0	🟢	Not approved as drug in US. Human evidence: Russian Khavinson lab research only. Community use modest.	Standard Khavinson bioregulator safety pattern. No significant adverse event patterns documented.
Limited	Vesugen	Bioregulator	Cardiovascular / Vascular	Khavinson tripeptide bioregulator targeting vascular tissue. Mechanism includes peptide-bioregulator modulation of endothelial function. Available in topical formulations (e.g., Vesilute eye drops) and injectable forms.	3.8	5.2	🟢	Not approved as drug in US. Human evidence: Russian Khavinson lab research only. Modest community use in vascular health and ocular contexts.	Standard Khavinson bioregulator safety pattern. No significant adverse event patterns documented. Topical/ocular use particularly well-tolerated.
Limited	Other Khavinson Bioregulators (Bronchogen, Cardiogen, Chonluten, Ovagen, Pancragen, Prostamax, Testagen, Vilon)	Bioregulator	Various (organ-specific)	Khavinson family of short peptide bioregulators (typically tri- or tetrapeptides) each targeting specific organ tissues based on derivation. Mechanisms involve peptide-bioregulator modulation of organ-specific gene expression and tissue function.	3.7	4.8	🟢	Not approved as drugs in US. Human evidence: Russian Khavinson lab research only; standard single-lab dominance pattern across all variants. Community use varies by organ target; modest overall presence.	Standard Khavinson bioregulator safety pattern across the family. No significant adverse event patterns documented. Long-term safety data limited to Russian sources.
Limited	Fenbendazole	Small Molecule	Anti-parasitic / Cancer-adjuvant	Veterinary benzimidazole antiparasitic. Mechanism includes tubulin disruption — same as mebendazole. Off-label human cancer-adjuvant use driven by community protocols.	3.8	6.0	🟡	Approved for veterinary use; off-label human use is unvalidated. Human evidence: preclinical tubulin disruption evidence in cancer cell lines; community case reports; no human RCTs. Significant alternative-cancer-protocol community use.	Hepatotoxicity at the higher doses used in cancer-adjuvant protocols. Liver function monitoring essential for off-label use. Generally safe at standard parasitic doses with decades of veterinary safety data. Off-label oncology dosing is where concerns concentrate.
Limited	TB-500 Frag	Peptide Fragment	Injury Recovery	7-amino-acid core fragment of TB-500. Mechanism extrapolated from parent compound at lower potency.	3.5	4.5	🟡	Not FDA-approved. Human evidence: less than parent TB-500. Community use minimal compared to full TB-500.	Less safety data than parent TB-500. Same theoretical tumor concern. Lower potency may mean lower risk but also unknown dose-response.
Limited	HGH Frag (176-191)	Peptide Fragment	Weight Loss	C-terminal HGH fragment historically marketed as "fat loss without growth effects." Same molecular identity as AOD9604; both reference compounds covering the failed Phase 2b trial.	3.5	4.0	🟢	Same compound as AOD9604; Phase 2b trial that tested this fragment failed primary endpoint. Human evidence: failed Phase 2b trial. Should be considered alongside AOD9604.	Phase 2b safety profile was clean — the trial showed lack of efficacy, not safety concerns. Generally well-tolerated.
Limited	DSIP	Peptide	Sleep / Nootropic	Delta sleep-inducing peptide. Isolated 1977. Mechanism unclear despite decades of research. Studied for sleep and stress modulation.	3.5	4.5	🟢	Not FDA-approved. Human evidence: 50 years of sporadic clinical research without clinical breakthrough. Community sleep-aid use modest.	50 years of sporadic clinical use without significant safety signals. Endogenous peptide. Generally well-tolerated despite efficacy questions.
Weak	Glutathione	Tripeptide / Antioxidant	Antioxidant / Anti-aging	Endogenous redox tripeptide. Oral bioavailability minimal; IV delivery is the wellness-clinic standard. Studied for antioxidant support, liver function, and skin brightening.	3.5	5.5	🟢	Endogenous tripeptide; available as supplement and through compounding pharmacies. Human evidence: extensive on biochemistry; thin on supplemented forms producing meaningful intracellular elevation due to bioavailability. Wellness IV adoption widespread despite weak clinical evidence.	IV use occasionally causes sulfur-related side effects (taste, smell, mild flushing). Oral has minimal absorption so minimal effect of any kind. Skin-brightening high-dose use has theoretical kidney concerns but rarely documented in practice.
Weak	GHRP-2	Peptide	GH / Growth	First-generation synthetic ghrelin receptor agonist. Mechanism includes GH release via ghrelin receptor; also raises cortisol, prolactin, and appetite. Made largely obsolete by ipamorelin.	2.5	3.5	🟡	Not FDA-approved. Expected to REMAIN on FDA Category 2. Human evidence: pharmacology characterized; clinical use largely abandoned in favor of ipamorelin.	Cortisol and prolactin elevation are real and unwanted. Appetite stimulation can drive overeating in some users. Otherwise tolerable but the side effect profile is why ipamorelin replaced it.
Weak	GHRP-6	Peptide	GH / Growth	Older sibling of GHRP-2. Similar mechanism with even more appetite stimulation. Made obsolete by ipamorelin.	2.5	3.0	🟡	Not FDA-approved. Expected to REMAIN on FDA Category 2. Human evidence: pharmacology characterized; clinical use largely abandoned.	Same profile as GHRP-2 with worse appetite stimulation. Cortisol/prolactin issues. Not dangerous, just unpleasant and obsolete.
Weak	5-Amino-1MQ	Small Molecule	Weight Loss / Metabolic	Small-molecule NNMT inhibitor. Mechanism modulates adipocyte methylation patterns. Reproducible mouse data on body composition; no published human trials.	2.5	4.0	🟠	Not approved in any jurisdiction; sold as research chemical. Human evidence: animal/preclinical only; zero published human trials. Recent community side-effect reports accumulating.	Recent community reports of side effects including liver enzyme elevation, mood changes, fatigue. NNMT inhibition has broad metabolic effects not fully characterized in humans. Insufficient safety data given absent human trials.
Weak	AICAR	Small Molecule	Mitochondrial / Metabolic	AMPK activator. Mechanism mimics low cellular energy state activating AMPK pathway. Marketed as "exercise in a pill." Banned in sport.	2.5	3.8	🟡	Not FDA-approved. WADA-banned. Human evidence: preclinical extensive; thin controlled human data despite years of community use.	Limited human safety data. Theoretical concerns about pathological AMPK activation. Generally well-tolerated in available reports but long-term effects unclear. WADA ban reflects performance-enhancement concerns rather than documented harm.
Weak	SLU-PP-332	Small Molecule	Mitochondrial / Metabolic	ERR agonist. Mechanism mimics endurance exercise effects on mitochondrial biogenesis and fatty acid oxidation. Marketed as "exercise mimetic." Preclinical-stage compound.	2.5	4.0	🟡	Not approved in any jurisdiction; sold as research chemical. Human evidence: zero human trials; mouse data shows endurance-mimetic effects. Recent community attention has accelerated use ahead of safety data.	No human safety data available. Theoretical concerns about chronic ERR receptor activation effects. Animal data shows promising metabolic effects without obvious toxicity, but human dose-response and long-term effects are completely uncharacterized.
Weak	SNAP-8	Peptide	Skin / Cosmetic	Acetyl octapeptide-3 marketed as topical "botox alternative." Mechanism proposed as SNARE protein interference. Topical use only.	2.5	3.0	🟢	Not approved as drug; available as cosmetic ingredient. Human evidence: marketed claims significantly outrun published data. Topical only with limited community traction.	Topical only, generally well-tolerated. Skin irritation occasionally. The issue is efficacy, not safety.
Weak	Dihexa	Small Molecule	Nootropic / Cognitive	Small-molecule HGF mimetic. Mechanism activates HGF receptor (Met). Rodent nootropic with zero human trials. HGF pathway activation is a named oncology concern.	2.0	3.5	🔴	Not approved in any jurisdiction; sold as research chemical. Human evidence: animal/preclinical only. HGF pathway activation is well-documented in cancer progression.	HGF-mimetic mechanism is a named oncology concern — HGF pathway activation is well-documented in cancer progression. Zero human safety trials. Combination of speculative oncology risk with absent safety data drives significant concerns classification despite no documented harm yet — because the data simply does not exist.
Concerns	FOXO4-DRI	Peptide	Senolytic / Longevity	Synthetic FOXO4 D-retro-inverso peptide. Mechanism disrupts FOXO4-p53 interaction to selectively trigger apoptosis in senescent cells. Studied as senolytic in preclinical models.	2.0	4.0	🔴	Not approved in any jurisdiction; sold as research chemical. Human evidence: zero human clinical trials. Mechanism is theoretically promising for cellular senescence but unvalidated in humans. Community use accelerating ahead of safety data.	Zero human safety data. Senolytic mechanism is novel and broadly active — targeting cellular apoptosis pathways without clinical guardrails carries unknown risks. Animal data is promising but does not establish safety windows.
Concerns	ACE-031	Peptide / Protein	Muscle / Performance	Soluble activin receptor type IIB. Mechanism includes myostatin and activin pathway inhibition. Developed for muscular dystrophy; Phase 2 trial terminated 2011 due to vascular safety concerns.	1.5	2.5	🔴	Phase 2 trial terminated by sponsor in 2011 due to vascular safety concerns (nosebleeds, gum bleeding, dilated blood vessels). Not approved in any jurisdiction. Continued community use despite documented trial termination.	Real documented safety concerns from terminated clinical trial: vascular events including epistaxis and gingival bleeding. Mechanism may affect vascular permeability and angiogenesis in ways not fully characterized. Trial termination is meaningful regulatory signal.
Concerns	Follistatin-344	Protein / Gene Therapy	Muscle / Performance	Myostatin inhibitor. Retail injectable has zero human performance trials. Some channels distribute as untested gene therapy formulation with different risk profile entirely.	1.0	2.0	🔴	Not approved in any jurisdiction; sold as research chemical or untested gene therapy in some channels. Human evidence: zero controlled human trials on retail product. Bodybuilding fringe use despite safety concerns.	Gene-therapy versions sold in some channels are categorically different from recombinant protein — and carry serious risks given untested status. Myostatin suppression has theoretical concerns about cardiac muscle, tendon strength, glucose metabolism. Zero controlled human safety data on retail product.
Concerns	IGF-1 LR3	Peptide / Protein	Muscle / Performance	Long-acting IGF-1 analog with extended half-life. Mechanism drives sustained supraphysiologic IGF-1 elevation. WADA banned. The clearest cancer-risk signal of any commonly-discussed peptide.	1.0	2.5	⚫	Not approved in any jurisdiction; sold as research chemical. WADA-banned. Human evidence: extensive on IGF-1 biology including epidemiologic cancer associations across multiple tumor types. Persistent bodybuilding community use despite documented risks.	Sustained IGF-1 elevation has the clearest cancer-risk signal of any commonly-used peptide — epidemiologic data on elevated IGF-1 and cancer incidence is consistent across multiple tumor types. Unlike theoretical concerns about other compounds, the IGF-1 elevation cancer link has real epidemiologic backing. Hypoglycemia at high doses. WADA banned for substantive reasons.

Methodology

Evidence Tier Classifications

Evidence Tier classifications describe the strength and depth of evidence supporting each compound. They are not recommendations for or against use. Tier placement reflects published research, regulatory status, and documented evidence — not endorsement.

Elite — drug-tier evidence; multiple Phase 3 trials; FDA approval; hard outcome data
Strong — strong evidence base; FDA approval or near-approval; well-characterized mechanism
Solid — real science with mixed results; Phase 2 evidence or foreign-jurisdiction approval
Limited — off-label or thin data; mechanism plausible but human evidence sparse
Weak — minimal human evidence; claims significantly outrun data
Concerns — documented safety concerns or insufficient evidence combined with elevated risk

Evidence Score (10-point scale)

The Evidence Score reflects the rigor and depth of evidence supporting each compound, weighted as follows:

Clinical Evidence Quality (35%) — Phase 3 RCT > Phase 2 RCT > Phase 1 / small observational > preclinical animal > in vitro > anecdotal
Regulatory Status & Approval (20%) — FDA approval, foreign-jurisdiction approval, reclassification status
Safety Profile & Documented Tolerability (20%) — adverse event rates, real-world adherence, contraindications, long-term safety data
Mechanism Plausibility & Translational Validity (10%) — does the mechanism translate from cells/animals to humans
Real-World Tolerability & Adherence (10%) — trial efficacy vs. real-world outcomes
Single-Lab / Single-Source Dominance Penalty (5%) — replication risk when evidence concentrates in one research group

Adoption Pattern Score (10-point scale)

The Adoption Pattern Score reflects how broadly a compound is used in clinical practice, functional medicine settings, and the broader research community. It is not a measure of efficacy, safety, or appropriateness for any individual user — only of how widely the compound is currently in use. Anecdotal reports and community usage do not constitute evidence of efficacy.

Functional medicine and clinic adoption (25%)
Patient-reported outcome consistency (20%)
Time-tested use (20%) — multi-decade clinical use abroad weighted here
Mechanism alignment with reported outcomes (15%)
Cost-of-failure profile (15%)
Single-lab dominance penalty (5%)

Adverse Event Profile Classifications

The Adverse Event Profile column reflects documented patterns from published trials, regulatory surveillance, and clinical and community reports. It is not a safety endorsement for any individual user; individual risk depends on personal health status, concurrent medications, and clinical context that this commentary cannot assess.

🟢 Minimal Documented Risk — decades of safety data or excellent profile; minimal real-world concerns
🟡 Manageable with Awareness — real but manageable concerns with informed use
🟠 Notable Concerns Documented — meaningful concerns warranting cautious use
🔴 Significant Concerns Documented — serious documented adverse events; benefits typically outweighed by risks
⚫ Serious Documented Concerns — safety profile genuinely concerning even with supervision

Research-Use-Only Vendors

Tier	Vendor	Score	Lab Stack	Key Reasoning
Top	Glacier Aminos	8.4	Kovera Labs, Freedom Diagnostics	Publicly disclosed comprehensive testing program covering purity, quantity, heavy metals, and endotoxin per batch. Family-owned, US-based operation. Consistent positive customer feedback in publicly available reviews. QR-coded batch documentation linking to lot-specific COAs.
Top	Peptidology	7.8	Vanguard Laboratory, Eagle Analytical Services	Uses two ISO/IEC 17025:2017 accredited labs — among the strongest lab stack combinations in the market. Eagle Analytical Services is FDA + DEA registered with pharmaceutical-grade methodology. High-volume per-batch testing across purity, content, identity, endotoxin, elemental impurities, and microbial sterility. Multi-point analytical verification program. Account-gated catalog. Established researcher community.
Top	Orbitrex Peptides	7.7	Freedom Diagnostics, Chromate, TrustPointe Analytics, Kovera Labs	Externally validated through independent third-party testing programs visible in public databases. Veteran-owned operation. QR-coded vials linking to batch-specific COAs. Publicly demonstrated transparent handling of analytical corrections. Customer testing credit program for independent verification.
High	Skye Peptides	7.4	Janoshik Analytical, MZ Biolabs, TrustPointe Analytics	Three named lab partners across multiple analytical categories. Public test reports page with batch-matched coverage. External validation through independent third-party testing on multiple products.
High	Kimera Chems	7.4	MZ Biolabs, TrustPointe Analytics, Freedom Diagnostics, Vanguard Laboratory	Four named lab partners across multiple analytical categories — among the broader lab stacks in this market, including one ISO 17025-accredited lab. Long operational tenure, broad catalog. Recent customer-service engagement on technical questions shows operational maturity. Some publicly documented customer service incidents are real considerations worth reader awareness.
High	OROS Research	7.1	Ethos Analytics, Freedom Diagnostics, Vanguard Laboratory	Uses two ISO 17025–accredited labs (Ethos and Vanguard) paired with a mid-tier partner — strong lab stack overall. Multi-panel testing protocol per product page. BBB-registered LLC with named co-founders. Manufacturing transparency claims. Held below top tier due to shorter operational track record.
High	Pure Peptides	6.9	MZ Biolabs (publicly named)	Publicly names lab partner. Public document layer with COA assets across catalog. Positive customer feedback trajectory in publicly available reviews. Bulk pricing structure.
High	Peptide Partners	6.8	TrustPointe Analytics, BioRegen, Chromate, Kovera Labs	Multiple named lab partners across analytical categories. Demonstrated quality discipline through publicly known incidents where batches were discarded after analytical findings. A 2026 adverse reaction incident with weak response remains a publicly known operational consideration worth reader awareness.
Mid	Oath Research	6.7	Unnamed "accredited US labs"	Polished documentation framework with formal published research supply standard, batch-lookup tool, and refund/replacement policy. Lab partner not publicly named. ISO-related language in marketing is general rather than specific.
Mid	Evolve Peptides	6.7	Unnamed "independent accredited laboratories"	Customer-initiated third-party verification policy is a publicly disclosed quality-confidence signal. Clean customer feedback trajectory in publicly available reviews. Published affiliate program with disclosed commission rate.
Mid	Peptide Supply Co	6.6	Lab partner not publicly named	Independent batch testing claimed, public COA section, fast US shipping. Smaller community footprint and limited third-party verification visibility.
Mid	Blank Peptides	6.5	Tennessee-based testing partner	Mid-tier lab caps the score. Missouri manufacturing claim is unusually transparent for supply-chain visibility. Money-back guarantee on unopened products is rare in this market. Minimal operational track record.
Mid	Instant Peptides	6.5	Kovera Labs (with publicly discussed independence considerations specific to this vendor relationship)	Multi-panel testing protocol on paper. Established customer base, batch lookup tool. Community discussion has raised independence considerations about this specific vendor-lab relationship that warrant reader verification — consideration is specific to this vendor's lab relationship rather than to either party broadly.
Mid	Synthesis Peptides	6.2	Unnamed labs	Clean customer feedback in publicly available reviews and operational presentation. Limited public COA archive, no named lab partner, limited methodology specifics published. COAs available upon request rather than via public archive.
Mid	Peak Peptide	6.2	Lab partner not publicly named	Positive customer feedback trajectory in publicly available reviews. Fast shipping. Limited third-party verification visibility, no named accredited lab partner.
Mid	Peptide Plugs	6.0	Lab partner not publicly named	Third-party tested per vendor disclosure. Owner-engaged customer service noted in publicly available reviews. Batch-linked documentation. Limited external verification, lab partner not publicly named in accessible materials.
Low-Mid	Crush Research	5.8	Mixed: includes one ISO 17025 accredited lab plus mid-tier labs	Public testing page with named outside labs. Positive customer feedback trajectory in smaller review sample. Owner-engaged operation. Mid-tier lab mix overall.
Low-Mid	Polaris Peptides	5.5	Lab partner not publicly named	External testing results from independent third-party programs show inconsistency across catalog. Less than two years of operational history, no proactive COA publication. Refer to public third-party testing databases for product-specific results.
Low	Eternal Peptides	5.5	Janoshik Analytical (publicly named)	Uses a publicly named third-party lab with posted COAs covering multiple panels. External validation exists in public third-party testing databases. Lower review volume than top vendors.
Low	Simple Peptide	5.4	Freedom Diagnostics	Heavy affiliate-driven marketing. Documented quality-control concerns in publicly available reviews. Reader should consult public review sources directly for specifics.
Low	Elite Research USA	5.2	In-house COAs only	External testing results from independent third-party programs show quality inconsistency across catalog. In-house testing rather than third-party. Manufacturing claims not externally substantiated.
Low	Mile High Compounds	5.0	Lab partner not publicly named	Substantial customer feedback volume in publicly available reviews. Comprehensive testing claimed. No independent third-party verification visible, no named accredited lab partner.
Low	Hydro Research	4.8	Dual third-party (not publicly named)	Substantial customer feedback volume in publicly available reviews. Dual third-party testing claimed including endotoxin. Underlying lab partners not transparently disclosed.

Methodology

Lab quality & independence (35%) — ISO 17025–accredited lab is the strongest signal; named lab partners beat unnamed
COA transparency (20%) — public per-batch archive with QR/lookup beats request-only documentation
Incident history & operational integrity (20%) — how problems are handled; pattern complaints; documented technical failures
Community feedback signal quality (15%) — cross-referenced across publicly available review sources, weighted by independence
Manufacturing claims & supply-chain transparency (10%) — named manufacturing location beats vague or absent claims

Testing Labs

Tier	Lab	Score	Key Reasoning
Top	Eagle Analytical Services	9.0	FDA + DEA registered, A2LA ISO 17025:2017 accredited, 80,000+ sq ft facility, 20+ years operating. Serves 503A/503B compounders — methodology meets regulatory submission standards. Pharmaceutical-grade tier.
Top	Ethos Analytics	8.9	ISO/IEC 17025:2017 accredited, FDA-registered, department-of-health certified. Dedicated peptide purity/quantitation services. Strong current peptide-community reputation. Best dedicated peptide-focused accredited lab in active use.
Top	Prime Analytical Laboratories (PAL)	8.3	FDA-registered, GMP/GLP-compliant, ISO/IEC 17025:2017 accredited via PJLA, 30+ years leadership experience. Full instrument stack (Shimadzu triple-quad LC-MS, Agilent HPLC, Thermo ICP-MS). Genuinely pharma-grade.
High	Vanguard Laboratory	8.0	A2LA ISO/IEC 17025:2017 + Washington Department of Ecology + Department of Health for Controlled Substances triple-accreditation stack. USP <1225>-validated HPLC, Ph.D. chemist review, full peptide panel.
High	MZ Biolabs	7.8	DEA Schedule III licensed, US-based, top-shelf instrumentation. Documented accuracy in cross-comparison studies. No ISO 17025 accreditation and purity-only scope (no endotoxin/sterility/heavy metals) caps the ceiling.
High	TrustPointe Analytics	7.6	Real lab in Dorr, MI, founded by pharmaceutical-industry chemist. Two-person quality review chain on COAs. USP <71> compliant sterility testing, sophisticated methodology disclosures. Validated via multi-lab cross-comparison studies. Demonstrated real-world impact catching analytical findings that drove vendor batch decisions.
High	Kovera Labs	7.5	Real Illinois lab offering comprehensive multi-panel testing: HPLC purity with three-vial batch conformity, LC-MS identity, Charles River Endosafe endotoxin (USP <85>), BacT/ALERT 14-day sterility (USP <71>), ICP-MS heavy metals (USP <232>/<233>), fentanyl screening. Verification portal with QR codes and access codes. Capped from top tier by no public ISO 17025 accreditation.
High	Janoshik Analytical	7.4	Community-standard lab with QR-code COA verification system preventing forgery. Documented accuracy, reasonable pricing. Czech-based, no ISO 17025. Methodology details minimal in public materials, raw data behind paywall.
High	ACS Peptide Testing Labs	7.2	Dedicated Florida peptide testing operation. HPLC + ESI mass spec + contaminant screening + full COA reports. Strong peptide-specific focus. Less verifiable independent track record than ISO 17025 accredited labs.
High	ILS Laboratories	7.0	ISO 17025 accredited with peptide focus. Less frequently discussed in community channels but present in multiple vendors' published COA archives.
High	Purity Laboratories	6.8	ISO 17025 accredited, supplement/peptide focus. Less peptide-specific volume than dedicated peptide labs.
Mid	Freedom Diagnostics	5.6	Founded 2023, Franklin TN, public COA database, 24-48 hour turnaround claim is unusually fast for full HPLC/MS workflow. Accreditation depth and method validation status not publicly documented. Heavy marketing relative to documentation transparency.
Mid	Peptide Test	4.4	Small, peptide-focused service. Limited public reputation, limited track record, limited accreditation transparency.

Methodology

Accreditation strength & scope (35%) — ISO/IEC 17025:2017 from A2LA or PJLA with peptide methods in scope is the bar; FDA/DEA registration is a strong secondary signal
Methodology depth & instrumentation (25%) — HPLC + high-resolution MS + USP-aligned endotoxin/heavy metals/sterility; method validation status matters
Independence from vendors (20%) — operational independence is critical; labs with ownership or registration overlap with vendors are compromised regardless of COA quality
Track record & community verification (10%) — documented accuracy on blind samples; longevity in the space
Transparency of process (10%) — verification portals, published methodology, willingness to share raw data

Disclaimer

This page is editorial commentary and informational synthesis for educational purposes only. Nothing here constitutes medical, legal, commercial, therapeutic, or analytical advice.

The compounds discussed include FDA-approved drugs, research chemicals, and substances with varying regulatory status; some are not approved for human use in the United States. All discussion of mechanisms, pathways, and theoretical applications is general in nature and does not directly or indirectly imply human use, outcomes, benefits, or efficacy of any compound or product. No claims are made regarding FDA approval status beyond what is publicly documented.

Vendors discussed sell products marketed as research-use-only and not intended for human consumption, medical diagnosis, treatment, or therapeutic use. Laboratories discussed provide analytical services to the research and commercial chemistry markets. Mention of any compound, vendor, or laboratory is not an endorsement, recommendation, or guarantee of quality, safety, purity, accuracy, or fitness for any purpose; inclusion reflects only that the entity is publicly discussed in the relevant research and commerce contexts.

This page does not paraphrase, summarize, or restate analytical results, Certificates of Analysis, or testing data for any specific vendor product. For product-specific analytical information, readers should consult vendors' official websites, published materials, or independent third-party testing databases directly. Commentary on vendors and labs reflects general operational practices, testing program scope, lab partnerships, accreditation status, and publicly known characteristics — not validation of any specific analytical result.

Tier classifications, scores, and reasoning presented here are educational commentary based on publicly available information as of May 2026 and are subject to change as new evidence, regulatory decisions, and operational developments emerge.

I encourage readers to independently verify vendor and lab practices, including current testing programs, lab partnerships, accreditation status, methodology, and operational integrity, before making any research sourcing or analytical decisions. The information presented here reflects publicly available data and personal commentary; it may not reflect current practices.

Always consult qualified clinicians before making any health decision.

*Last reviewed: May 2026*